DexCom showed strong growth, margin expansion, and Stelo's OTC launch unlocked new markets despite competitive and regulatory ...

The diabetes tech firm tailored its software to the 25 million people in the U.S. who have Type 2 diabetes and do not use insulin. The device is similar to existing prescription CGMs. Users pair the ...

LONDON--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...

Dexcom raised its sales expectations for 2025 amid expanding access to its glucose sensors for people with Type 2 diabetes. The company raised its revenue forecast to a range of $4.6 billion to about ...

DexCom, Inc. DXCM announced that its DexCom ONE continuous glucose monitoring (CGM) system has been launched in France for people with diabetes. The latest CGM sensor from the company’s portfolio has ...

DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ ...

DexCom Inc. DXCM recently introduced a new direct-to-Apple-Watch feature for its G7 continuous glucose monitor (CGM) users. With the new feature, G7 is likely to be the first CGM device that can link ...

No-moat Dexcom delivered another quarter of solid results, and full-year performance hit our 2022 revenue estimate and gross margin on the nose. However, the absence of spending on collaborative ...

DexCom has a well-established record of introducing the most precise sensors for use in its continuous glucose monitors. On the strength of its technology, DexCom has captured an impressive slice of ...

We recently published 10 Stocks Bleeding Early. DexCom, Inc. (NASDAQ:DXCM) is one of the companies that stood stronger last week. DexCom fell for a fifth straight day on Monday, shedding 3.82 percent ...